# To Evaluate the Beneficial Effect of Probiotics on DKD Patients and the Role of Gut Microbiota Modulation

> **NCT05674981** · NA · COMPLETED · sponsor: **GenMont Biotech Incorporation** · enrollment: 50 (actual)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DIETARY_SUPPLEMENT:** Probiotic group
- **OTHER:** Placebo group

## Key facts

- **NCT ID:** NCT05674981
- **Lead sponsor:** GenMont Biotech Incorporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-24
- **Primary completion:** 2025-04-24
- **Final completion:** 2025-05-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05674981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05674981, "To Evaluate the Beneficial Effect of Probiotics on DKD Patients and the Role of Gut Microbiota Modulation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05674981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*